Valuation: Resverlogix Corp.

Market Cap 23.28M 16.6M 14.41M 13.4M 12.32M 1.58B 23.67M 158M 61.98M 789M 62.38M 61.01M 2.61B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 109M 77.75M 67.51M 62.76M 57.72M 7.42B 111M 740M 290M 3.7B 292M 286M 12.25B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 day-5.00%
1 week-5.00%
Current month+5.56%
1 month+5.56%
3 months-5.00%
6 months-9.52%
Current year-5.00%
1 week 0.1
Extreme 0.095
0.1
1 month 0.09
Extreme 0.09
0.11
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Option

Chief Financial Officer

350,000 0.1018%
06/07/26 Option

Chief Financial Officer

-350,000 0.1018%
06/07/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%-5.00%+5.56%-9.52% 24.54M
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.44%-1.61%-17.69%-15.68% 23.48B
-2.85%-8.20%-6.26%+361.83% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-2.39%+26.99%-31.34% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-5.25%-4.71%+43.89%+167.15% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average -0.61%-1.29%+32.70%+141.54% 23.35B
Weighted average by Cap. +0.17%+0.09%+31.05%+122.79%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.44M -4.73M -4.39M -4.04M -519M -7.76M -51.8M -20.32M -259M -20.45M -20.01M -857M -7.77M -5.54M -4.81M -4.47M -4.11M -528M -7.9M -52.69M -20.67M -263M -20.81M -20.35M -872M
Net Debt 81.87M 58.36M 50.67M 47.11M 43.32M 5.57B 83.24M 555M 218M 2.78B 219M 215M 9.19B 85.79M 61.15M 53.1M 49.36M 45.4M 5.83B 87.22M 582M 228M 2.91B 230M 225M 9.63B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
31/07/26 CA$0.0950 -5.00% 14,943
30/07/26 CA$0.1000 -.--% 117,000
28/07/26 CA$0.1000 -4.76% 520
24/07/26 CA$0.1050 +5.00% 37,116
23/07/26 CA$0.1000 -4.76% 43,914